“Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III RenalCell Carcinoma” (2026) Journal of Kidney Cancer, 13(2), pp. 21–28. doi:10.15586/jkcvhl.v13i2.455.